CellSource Co., Ltd. Fundamental Analysis (JPX: 4880.T)
CellSource Co., Ltd. (JPX: 4880.T) shows weak financial fundamentals with a PE ratio of 97.47, profit margin of 1.93%, and ROE of 1.18%. The company generates $3.7B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 4880.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4880.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate4880.T shows balanced valuation metrics.
Growth Score
Moderate4880.T shows steady but slowing expansion.
Financial Health Score
Excellent4880.T maintains a strong and stable balance sheet.
Profitability Score
Moderate4880.T maintains healthy but balanced margins.
Key Financial Metrics
Is 4880.T Expensive or Cheap?
P/E Ratio
4880.T trades at 97.47 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 4880.T's PEG of 0.07 indicates potential undervaluation.
Price to Book
The market values CellSource Co., Ltd. at 1.15 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 24.83 times EBITDA. This signals the market has high growth expectations.
How Well Does 4880.T Make Money?
Net Profit Margin
For every $100 in sales, CellSource Co., Ltd. keeps $1.93 as profit after all expenses.
Operating Margin
Core operations generate 7.51 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.18 in profit for every $100 of shareholder equity.
ROA
CellSource Co., Ltd. generates $1.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CellSource Co., Ltd. generates limited operating cash flow of $333.22M, signaling weaker underlying cash strength.
Free Cash Flow
CellSource Co., Ltd. produces free cash flow of $290.01M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $14.61 in free cash annually.
FCF Yield
4880.T converts 4.21% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
97.47
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.07
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.15
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.004
vs 25 benchmark
Current Ratio
Current assets to current liabilities
10.97
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How 4880.T Stacks Against Its Sector Peers
| Metric | 4880.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 97.47 | 32.14 | Worse (Expensive) |
| ROE | 1.18% | 550.00% | Weak |
| Net Margin | 1.93% | 30133.00% | Weak |
| Debt/Equity | 0.00 | 0.56 | Strong (Low Leverage) |
| Current Ratio | 10.97 | 5.70 | Strong Liquidity |
| ROA | 1.01% | 3.00% | Weak |
4880.T outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CellSource Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation